Page 111 - 2019_01-Haematologica-web

Pleural effusion in dasatinib-treated CML patients
ure of imatinib therapy. Blood. 2007;
109(6):2303-2309.
28. Kantarjian H, Pasquini R, Hamerschlak N,
et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a random- ized phase 2 trial. Blood. 2007;109(12): 5143-5150.
29. Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects. [clinicaltrials.gov identifier: NCT00529763]. https: //clinicaltrials. gov/ct2/show/NCT00529763?term=00529 763&rank=1. Accessed October 11, 2017.
30. Trudel GC, Paliwal P, Lainas I. Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diag- nosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): design of CA180-363, a phase II open-label randomized trial. J Clin Oncol. 2012;20(15 suppl):abstr TSP6634.
31. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia
chromosome-positive leukemias. N Engl J
Med. 2006;354(24):2531-2541.
32. National Cancer Institute. Common
Terminology Criteria for Adverse Events (CTCAE) 3.0; 2006. https:// ctep.cancer.gov/protocolDevelopment/elec tronic_applications/docs/ctcaev3.pdf. Accessed May 11, 2016.
33. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007; 176(8):814-818.
34. Cortes JE, Jimenez CA, Mauro M, et al. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma. 2017; 17(2):78-82.
35. Schiffer CA, Cortes J, Saglio G, et al. The association of dasatinib-induced lympho- cytosis with treatment outcome in patients with chronic myeloid leukemia (CML). Blood. 2013;122(21):2741.
36. La Rosée P, Martiat P, Leitner A, et al.
Improved tolerability by a modified inter- mittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol. 2013;92(10):1345-1350.
37. Cortes J, Hochhaus A, Kantarjian H, et al. Impact of dose reductions on 5-year effica- cy in newly diagnosed patients with chron- ic myeloid leukemia in chronic phase (CML-CP) from DASISION. Presented at the American Society of Clinical Oncology 2017 Annual Meeting; June 2-6, 2017; Chicago, IL.
38. Santos FP, Kantarjian H, Fava C, et al. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010; 150(3):303-312.
39. Iurlo A, Galimberti S, Abruzzese E, et al. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Ann Hematol. 2018;97(1):95-100.
haematologica | 2019; 104(1)
101